Home >> MARKETPLACE (page 2)

MARKETPLACE

New pathology lab products and industry news

Kurin specimen diversion technology

October 2018—Kurin announced the results of clinical data from hospitals that use its FDA-cleared blood culture diversion device. In studies conducted at Crouse Hospital, Syracuse, NY, and Bayfront Health, St. Petersburg, Fla., the hospitals saw an overall reduction—56 percent and 54 percent, respectively—in contaminated blood cultures inclusive of all cultures drawn with or without the device. When a Kurin set was used in the blood collection, Crouse saw an 89 percent reduction in contaminated blood cultures and Bayfront a 90 percent reduction in contaminated cultures. In both cases, the hospitals were already below the three percent national contamination rate benchmark when they began using Kurin. Using the company’s passive diversion technology, the hospitals’ overall contamination rates decreased to 0.8 percent and 1.2 percent, respectively. The company has also released a five-minute documentary film titled Cry Wolf: The Consequences of Blood Culture Contamination. The film addresses the prevalence of blood culture contamination, the clinical impact on patients, and the steep associated costs for hospitals. Cry Wolf can be viewed at www.betterbloodcultures.com.

Read More »

OGT expands sales support in Europe

October 2018—Oxford Gene Technology announced it is selling its Cytocell fluorescence in situ hybridization products through several affiliates of Sysmex Corp. in Europe. “The move is a testament to the ongoing successful integration of the two companies and commitment to combine efforts to support and serve end users,” according to a press release from OGT.

Read More »

FDA-approved cancer therapies

October 2018—The Food and Drug Administration approved moxetumomab pasudotox-tdfk (Lumoxity, AstraZeneca), a CD22-directed cytotoxin indicated for adult patients with relapsed or refractory hairy cell leukemia who received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

Read More »
X